Vivek Ramaswamy sold $8.5M of ROIV
owner at Roivant Sciences Ltd.. 748,230 shares at an average of $11.30, traded Jun 4, 2025, filed Jun 6, 2025.
Score components
- +12Role10% owner
- +25Trade size$8.5M at market
- 0Share of holdings soldSold 1.9% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002007997-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 4, 2025 | SOpen-market sale Common Shares | -547,430 | $11.34 | $6.2M | 38,627,181 | Jun 6, 2025 |
| Jun 6, 2025 | SOpen-market sale Common Shares | -200,800 | $11.19 | $2.2M | 38,426,381 | Jun 6, 2025 |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 53Moderate | Roivant Sciences Ltd. | Meghan Fitzgerald director | $1.9M 70,000 shares | -62% | |
| 68Notable | Roivant Sciences Ltd. | Epperly Melissa B director | $1.2M 41,861 shares | -73% | |
| 55Moderate | Roivant Sciences Ltd. | Daniel Allen Gold director | $33M 1,225,784 shares | -7% | |
| 55Moderate | Roivant Sciences Ltd. | Keith S Manchester director | $33M 1,225,784 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.